Details of the Drug

General Information of Drug (ID: DMM58JY)

• Drug Name: Ziprasidone
• Synonyms: 146939-27-7; Geodon; Zeldox; Ziprasidone hydrochloride; Ziprasidone [INN:BAN]; UNII-6UKA5VEJ6X; CP 88059; Ziprasidone mesylate trihydrate; 6UKA5VEJ6X; CHEMBL708; C21H21ClN4OS; CHEBI:10119; CP-88,059-1; ziprazidone; DSSTox_CID_3753; DSSTox_RID_77186; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; DSSTox_GSID_23753; ziprasidonum; ziprasidona; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one; Geodon; Zipradon; Ziprasidona; Ziprasidonum; Ziprazidone; CP 88059-01; Geodon (TN); Zeldox (TN); Zipradon (TN); Ziprasidone (INN); CP-88,059; CP-88059-1; CP-88,059-01; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; TC-5280

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1], [2], [3]

• Therapeutic Class: Antipsychotic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 412.9
  Topological Polar Surface Area (xlogp); 4
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2.6 h [4]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
  Bioavailability: The bioavailability of drug is 95.4% [4]
  Clearance: The sytemic clearance of drug is 7.5 mL/min/kg [6]
  Elimination: 0.5% of drug is excreted from urine in the unchanged form [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 7 hours [7]
  Metabolism: The drug is metabolized via the liver [8]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.3571 micromolar/kg/day [9]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.0012% [10]
  Vd: The volume of distribution (Vd) of drug is 1.5 L/kg [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.00043 mg/mL [5]
• Chemical Identifiers:
  Formula: C21H21ClN4OS
  IUPAC Name: 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
  Canonical SMILES: C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
  InChI: InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
  InChIKey: MVWVFYHBGMAFLY-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 60854
  ChEBI ID: CHEBI:10119
  CAS Number: 146939-27-7
  DrugBank ID: DB00246
  TTD ID: D0R1JV
  VARIDT ID: DR00810
  INTEDE ID: DR1732
  ACDINA ID: D00742

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[11]
Neuronal acetylcholine receptor alpha-7 (CHRNA7)	TTLA931	ACHA7_HUMAN	Binder	[1]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[12]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[13]
Aldehyde oxidase (AOX1) Main DME	DEAWHS8	AOXA_HUMAN	Substrate	[]

Molecular Expression Atlas of This Drug

• The Studied Disease: Schizophrenia
• ICD Disease Classification: 6A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.39E-02	1.07E-01	2.80E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ziprasidone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Quetiapine.	Schizophrenia [6A20]	[49]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Mesoridazine.	Schizophrenia [6A20]	[49]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Thioridazine.	Schizophrenia [6A20]	[49]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Aripiprazole.	Schizophrenia [6A20]	[50]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Iloperidone.	Schizophrenia [6A20]	[49]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Paliperidone.	Schizophrenia [6A20]	[49]
Loxapine	DM8AI9U	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Loxapine.	Schizophrenia [6A20]	[50]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Haloperidol.	Schizophrenia [6A20]	[49]
Perphenazine	DMA4MRX	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Perphenazine.	Schizophrenia [6A20]	[49]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Molindone.	Schizophrenia [6A20]	[50]
Chlorpromazine	DMBGZI3	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Chlorpromazine.	Schizophrenia [6A20]	[49]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Thiothixene.	Schizophrenia [6A20]	[50]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Clozapine.	Schizophrenia [6A20]	[49]
Trifluoperazine	DMKBYWI	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Trifluoperazine.	Schizophrenia [6A20]	[49]
Risperidone	DMN6DXL	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Risperidone.	Schizophrenia [6A20]	[49]
Olanzapine	DMPFN6Y	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Olanzapine.	Schizophrenia [6A20]	[50]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Amisulpride.	Schizophrenia [6A20]	[49]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Asenapine.	Schizophrenia [6A20]	[49]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Pimozide.	Schizophrenia [6A20]	[49]

Coadministration of a Drug Treating the Disease Different from Ziprasidone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Ivosidenib.	Acute myeloid leukaemia [2A60]	[49]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Midostaurin.	Acute myeloid leukaemia [2A60]	[49]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Idarubicin.	Acute myeloid leukaemia [2A60]	[49]
Daunorubicin	DMQUSBT	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Daunorubicin.	Acute myeloid leukaemia [2A60]	[49]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Arn-509.	Acute myeloid leukaemia [2A60]	[49]
Gilteritinib	DMWQ4MZ	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Gilteritinib.	Acute myeloid leukaemia [2A60]	[49]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Oliceridine.	Acute pain [MG31]	[49]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Scopolamine.	Addictive disorder [6C50-6C5Z]	[50]
Mitotane	DMU1GX0	Minor	Increased metabolism of Ziprasidone caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[51]
Terfenadine	DM4KLPT	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[49]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[52]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[52]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[50]
Tacrine	DM51FY6	Moderate	Antagonize the effect of Ziprasidone when combined with Tacrine.	Alzheimer disease [8A20]	[53]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Memantine.	Alzheimer disease [8A20]	[50]
Galantamine	DMEO794	Moderate	Antagonize the effect of Ziprasidone when combined with Galantamine.	Alzheimer disease [8A20]	[53]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Ziprasidone when combined with Rivastigmine.	Alzheimer disease [8A20]	[53]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Ziprasidone when combined with Donepezil.	Alzheimer disease [8A20]	[53]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Ziprasidone and Metronidazole.	Amoebiasis [1A36]	[54]
Trimethaphan	DMHF4IQ	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Trimethaphan.	Aneurysm/dissection [BD50]	[55]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Ivabradine.	Angina pectoris [BA40]	[56]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Bepridil.	Angina pectoris [BA40]	[49]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Dronedarone.	Angina pectoris [BA40]	[49]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Amyl nitrite.	Angina pectoris [BA40]	[57]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Nifedipine.	Angina pectoris [BA40]	[57]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[49]
Hydroxyzine	DMF8Y74	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[49]
Promazine	DMZAL7W	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Promazine.	Appearance/behaviour symptom [MB23]	[49]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Cilostazol.	Arterial occlusive disease [BD40]	[49]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Posaconazole.	Aspergillosis [1F20]	[49]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Ziprasidone and Levalbuterol.	Asthma [CA23]	[58]
Terbutaline	DMD4381	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Terbutaline.	Asthma [CA23]	[59]
Zafirlukast	DMHNQOG	Minor	Decreased metabolism of Ziprasidone caused by Zafirlukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[60]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Pirbuterol.	Asthma [CA23]	[59]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Ziprasidone and Salbutamol.	Asthma [CA23]	[61]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Formoterol.	Asthma [CA23]	[59]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[49]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[49]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Ciprofloxacin XR	DM2NLS9	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[49]
Dalfopristin	DM4LTKV	Minor	Decreased metabolism of Ziprasidone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[60]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[49]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Ziprasidone and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[49]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Chloramphenicol	DMFXEWT	Minor	Decreased metabolism of Ziprasidone caused by Chloramphenicol mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[60]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Capreomycin	DMNZBRY	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Capreomycin.	Bacterial infection [1A00-1C4Z]	[62]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Troleandomycin	DMUZNIG	Minor	Decreased metabolism of Ziprasidone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[60]
Lomefloxacin	DMVRH9C	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Telithromycin	DMZ4P3A	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Telithromycin.	Bacterial infection [1A00-1C4Z]	[49]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Retigabine.	Behcet disease [4A62]	[49]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Cariprazine.	Bipolar disorder [6A60]	[50]
Pexidartinib	DMS2J0Z	Minor	Increased metabolism of Ziprasidone caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[51]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Ziprasidone and Loperamide.	Bowel habit change [ME05]	[63]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Eribulin.	Breast cancer [2C60-2C6Y]	[49]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Lapatinib.	Breast cancer [2C60-2C6Y]	[49]
Tucatinib	DMBESUA	Minor	Decreased metabolism of Ziprasidone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[60]
Tamoxifen	DMLB0EZ	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Tamoxifen.	Breast cancer [2C60-2C6Y]	[49]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Toremifene.	Breast cancer [2C60-2C6Y]	[49]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Bosutinib.	Breast cancer [2C60-2C6Y]	[49]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Grepafloxacin.	Bronchitis [CA20]	[49]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Sotalol.	Cardiac arrhythmia [BC9Z]	[49]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Ziprasidone when combined with Acetylcholine.	Cataract [9B10]	[64]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[49]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[59]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Ziprasidone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[58]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Ziprasidone and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[59]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Ziprasidone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[59]
Phenylbutazone	DMAYL0T	Minor	Increased metabolism of Ziprasidone caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[51]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Ziprasidone and Dihydrocodeine.	Chronic pain [MG30]	[65]
Morphine	DMRMS0L	Major	Additive CNS depression effects by the combination of Ziprasidone and Morphine.	Chronic pain [MG30]	[66]
Oxaliplatin	DMQNWRD	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Oxaliplatin.	Colorectal cancer [2B91]	[49]
Panitumumab	DMQPD1F	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Panitumumab.	Colorectal cancer [2B91]	[62]
Isoproterenol	DMK7MEY	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Isoproterenol.	Conduction disorder [BC63]	[59]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Ziprasidone and Olopatadine.	Conjunctiva disorder [9A60]	[67]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Halothane.	Corneal disease [9A76-9A78]	[49]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Ziprasidone and Propofol.	Corneal disease [9A76-9A78]	[68]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Sevoflurane.	Corneal disease [9A76-9A78]	[49]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Ziprasidone and Remifentanil.	Corneal disease [9A76-9A78]	[66]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Probucol.	Coronary atherosclerosis [BA80]	[49]
Nimodipine	DMQ0RKZ	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Nimodipine.	Coronary vasospastic disease [BA85]	[57]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Methadone.	Cough [MD12]	[49]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Clofazimine.	Crohn disease [DD70]	[49]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Mifepristone.	Cushing syndrome [5A70]	[49]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Pasireotide.	Cushing syndrome [5A70]	[49]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Osilodrostat.	Cushing syndrome [5A70]	[49]
Aminoglutethimide	DMWFHMZ	Minor	Increased metabolism of Ziprasidone caused by Aminoglutethimide mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[51]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Ziprasidone and Ethanol.	Cystitis [GC00]	[67]
MK-8228	DMOB58Q	Minor	Decreased metabolism of Ziprasidone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[60]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Cyclandelate.	Dementia [6D80-6D8Z]	[57]
Aprepitant	DM053KT	Minor	Decreased metabolism of Ziprasidone caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[60]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Sertraline.	Depression [6A70-6A7Z]	[49]
Trimipramine	DM1SC8M	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Trimipramine.	Depression [6A70-6A7Z]	[49]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Cyclobenzaprine.	Depression [6A70-6A7Z]	[50]
Imipramine	DM2NUH3	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Imipramine.	Depression [6A70-6A7Z]	[49]
Fluoxetine	DM3PD2C	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Fluoxetine.	Depression [6A70-6A7Z]	[49]
Nortriptyline	DM4KDYJ	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Nortriptyline.	Depression [6A70-6A7Z]	[49]
Nefazodone	DM4ZS8M	Minor	Decreased metabolism of Ziprasidone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[60]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and OPC-34712.	Depression [6A70-6A7Z]	[50]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Clomipramine.	Depression [6A70-6A7Z]	[49]
Trazodone	DMK1GBJ	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Trazodone.	Depression [6A70-6A7Z]	[49]
Amitriptyline	DMK7F9S	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Amitriptyline.	Depression [6A70-6A7Z]	[49]
Amoxapine	DMKITQE	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Amoxapine.	Depression [6A70-6A7Z]	[49]
Mirtazapine	DML53ZJ	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Mirtazapine.	Depression [6A70-6A7Z]	[49]
Protriptyline	DMNHTZI	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Protriptyline.	Depression [6A70-6A7Z]	[49]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Doxepin.	Depression [6A70-6A7Z]	[49]
Griseofulvin	DMK54YG	Minor	Increased metabolism of Ziprasidone caused by Griseofulvin mediated induction of CYP450 enzyme.	Dermatophytosis [1F28]	[51]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Nitroglycerin.	Diabetic foot ulcer [BD54]	[57]
Hyoscyamine	DM804UR	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Hyoscyamine.	Digestive system disease [DE2Z]	[50]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Mepenzolate.	Digestive system disease [DE2Z]	[50]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Oxybutynine.	Discovery agent [N.A.]	[50]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[49]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Meclizine.	Dizziness and giddiness [MB48]	[50]
Trihexyphenidyl	DMB19L8	Moderate	Antagonize the effect of Ziprasidone when combined with Trihexyphenidyl.	Dystonic disorder [8A02]	[69]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Deutetrabenazine.	Dystonic disorder [8A02]	[49]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Ingrezza.	Dystonic disorder [8A02]	[49]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Ziprasidone and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[70]
Oxcarbazepine	DM5PU6O	Minor	Increased metabolism of Ziprasidone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[51]
Cenobamate	DMGOVHA	Minor	Increased metabolism of Ziprasidone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[51]
Phenytoin	DMNOKBV	Minor	Increased metabolism of Ziprasidone caused by Phenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[51]
Fosphenytoin	DMOX3LB	Minor	Increased metabolism of Ziprasidone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[51]
Carbamazepine	DMZOLBI	Minor	Increased metabolism of Ziprasidone caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[51]
Timolol	DM3NXRU	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Timolol.	Essential hypertension [BA00]	[57]
Guanabenz	DM5QWEL	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Guanabenz.	Essential hypertension [BA00]	[57]
Ethacrynic acid	DM60QMR	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Ethacrynic acid.	Essential hypertension [BA00]	[71]
Bendroflumethiazide	DM7EVLC	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Bendroflumethiazide.	Essential hypertension [BA00]	[62]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Phenoxybenzamine.	Essential hypertension [BA00]	[57]
Guanethidine	DM9NSWT	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Guanethidine.	Essential hypertension [BA00]	[57]
Nicardipine	DMCDYW7	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Nicardipine.	Essential hypertension [BA00]	[57]
Mecamylamine	DMGQFYB	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Mecamylamine.	Essential hypertension [BA00]	[57]
Benzthiazide	DMQWZ0H	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Benzthiazide.	Essential hypertension [BA00]	[62]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Nadolol.	Essential hypertension [BA00]	[57]
Tazemetostat	DMWP1BH	Minor	Increased metabolism of Ziprasidone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[51]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Solifenacin.	Functional bladder disorder [GC50]	[49]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Tolterodine.	Functional bladder disorder [GC50]	[50]
Darifenacin	DMWXLYZ	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Darifenacin.	Functional bladder disorder [GC50]	[50]
Itraconazole	DMCR1MV	Minor	Decreased metabolism of Ziprasidone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[60]
Pentamidine	DMHZJCG	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Pentamidine.	Fungal infection [1F29-1F2F]	[49]
Clotrimazole	DMMFCIH	Minor	Decreased metabolism of Ziprasidone caused by Clotrimazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[60]
Miconazole	DMPMYE8	Minor	Decreased metabolism of Ziprasidone caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[60]
Ketoconazole	DMPZI3Q	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Ketoconazole.	Fungal infection [1F29-1F2F]	[49]
Amphotericin B	DMTAJQE	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Amphotericin B.	Fungal infection [1F29-1F2F]	[62]
Phentolamine	DMXYJOB	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Phentolamine.	Gangrene [MC85]	[57]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Propantheline.	Gastric ulcer [DA60]	[50]
Cimetidine	DMH61ZB	Minor	Decreased metabolism of Ziprasidone caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[60]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[49]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[49]
Acetazolamide	DM1AF5U	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Acetazolamide.	Glaucoma [9C61]	[62]
Methazolamide	DM7J2TA	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Methazolamide.	Glaucoma [9C61]	[62]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Ziprasidone when combined with Isoflurophate.	Glaucoma [9C61]	[64]
Carteolol	DMFMDOB	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Carteolol.	Glaucoma [9C61]	[57]
Dichlorphenamide	DMH7IDQ	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Dichlorphenamide.	Glaucoma [9C61]	[71]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Ziprasidone and Brimonidine.	Glaucoma [9C61]	[72]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Ziprasidone when combined with Pilocarpine.	Glaucoma [9C61]	[64]
Sulfinpyrazone	DMEV954	Minor	Increased metabolism of Ziprasidone caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[51]
Spironolactone	DM2AQ5N	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Spironolactone.	Heart failure [BD10-BD1Z]	[57]
Triamterene	DM2HU9I	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Triamterene.	Heart failure [BD10-BD1Z]	[57]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Prazosin.	Heart failure [BD10-BD1Z]	[57]
Eplerenone	DMF0NQR	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Eplerenone.	Heart failure [BD10-BD1Z]	[57]
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Carvedilol.	Heart failure [BD10-BD1Z]	[57]
Chlorothiazide	DMLHESP	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Chlorothiazide.	Heart failure [BD10-BD1Z]	[62]
Furosemide	DMMQ8ZG	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Furosemide.	Heart failure [BD10-BD1Z]	[62]
Amiloride	DMRTSGP	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Amiloride.	Heart failure [BD10-BD1Z]	[57]
Bumetanide	DMRV7H0	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Bumetanide.	Heart failure [BD10-BD1Z]	[62]
Hydroflumethiazide	DMVPUQI	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[62]
Boceprevir	DMBSHMF	Minor	Decreased metabolism of Ziprasidone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[60]
Telaprevir	DMMRV29	Minor	Decreased metabolism of Ziprasidone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[60]
Isoniazid	DM5JVS3	Minor	Decreased metabolism of Ziprasidone caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[60]
Rifampin	DMA8J1G	Minor	Increased metabolism of Ziprasidone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[51]
Rifapentine	DMCHV4I	Minor	Increased metabolism of Ziprasidone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[51]
Delavirdine	DM3NF5G	Minor	Decreased metabolism of Ziprasidone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Fosamprenavir	DM4W9B3	Minor	Decreased metabolism of Ziprasidone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Cobicistat	DM6L4H2	Minor	Decreased metabolism of Ziprasidone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Etravirine	DMGV8QU	Minor	Increased metabolism of Ziprasidone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Amprenavir	DMLMXE0	Minor	Decreased metabolism of Ziprasidone caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Darunavir	DMN3GCH	Minor	Decreased metabolism of Ziprasidone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Atazanavir	DMSYRBX	Minor	Decreased metabolism of Ziprasidone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Ritonavir	DMU764S	Minor	Decreased metabolism of Ziprasidone caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Isosorbide mononitrate.	Hydrocephalus [8D64]	[57]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Eprosartan.	Hypertension [BA00-BA04]	[57]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Acebutolol.	Hypertension [BA00-BA04]	[57]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Moexipril.	Hypertension [BA00-BA04]	[57]
Bisoprolol	DM3UZ95	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Bisoprolol.	Hypertension [BA00-BA04]	[57]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Captopril.	Hypertension [BA00-BA04]	[57]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Penbutolol.	Hypertension [BA00-BA04]	[57]
Trandolapril	DM4L6EU	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Trandolapril.	Hypertension [BA00-BA04]	[57]
Methyldopa	DM5I621	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Methyldopa.	Hypertension [BA00-BA04]	[57]
Losartan	DM72JXH	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Losartan.	Hypertension [BA00-BA04]	[57]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Nebivolol.	Hypertension [BA00-BA04]	[57]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Levamlodipine.	Hypertension [BA00-BA04]	[57]
Fosinopril	DM9NJ52	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Fosinopril.	Hypertension [BA00-BA04]	[57]
Minoxidil	DMA2Z4F	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Minoxidil.	Hypertension [BA00-BA04]	[57]
Isradipine	DMA5XGH	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Isradipine.	Hypertension [BA00-BA04]	[57]
Verapamil	DMA7PEW	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Verapamil.	Hypertension [BA00-BA04]	[57]
Diltiazem	DMAI7ZV	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Diltiazem.	Hypertension [BA00-BA04]	[57]
Amlodipine	DMBDAZV	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Amlodipine.	Hypertension [BA00-BA04]	[57]
Fenoldopam	DMFAOKP	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Fenoldopam.	Hypertension [BA00-BA04]	[62]
Indapamide	DMGN1PW	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Indapamide.	Hypertension [BA00-BA04]	[62]
Benazepril	DMH1M9B	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Benazepril.	Hypertension [BA00-BA04]	[57]
Trichlormethiazide	DMHAQCO	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Trichlormethiazide.	Hypertension [BA00-BA04]	[62]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Diazoxide.	Hypertension [BA00-BA04]	[57]
Nitroprusside	DMM765C	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Nitroprusside.	Hypertension [BA00-BA04]	[57]
Enalapril	DMNFUZR	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Enalapril.	Hypertension [BA00-BA04]	[57]
Atenolol	DMNKG1Z	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Atenolol.	Hypertension [BA00-BA04]	[57]
Metoprolol	DMOJ0V6	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Metoprolol.	Hypertension [BA00-BA04]	[57]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Perindopril.	Hypertension [BA00-BA04]	[57]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Quinapril.	Hypertension [BA00-BA04]	[57]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Irbesartan.	Hypertension [BA00-BA04]	[57]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Hydralazine.	Hypertension [BA00-BA04]	[57]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Lisinopril.	Hypertension [BA00-BA04]	[57]
Hydrochlorothiazide	DMUSZHD	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[62]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Clevidipine butyrate.	Hypertension [BA00-BA04]	[57]
Conivaptan	DM1V329	Minor	Decreased metabolism of Ziprasidone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[60]
Fludrocortisone	DMUDIR8	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[62]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[50]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Amantadine.	Influenza [1E30-1E32]	[73]
Berotralstat	DMWA2DZ	Minor	Decreased metabolism of Ziprasidone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[60]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and ITI-007.	Insomnia [7A00-7A0Z]	[50]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[74]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Phenolphthalein.	Irritable bowel syndrome [DD91]	[49]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Clidinium.	Irritable bowel syndrome [DD91]	[50]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Dicyclomine.	Irritable bowel syndrome [DD91]	[50]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Ziprasidone when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[53]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Ziprasidone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[56]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Crizotinib.	Lung cancer [2C25]	[49]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Ceritinib.	Lung cancer [2C25]	[49]
PF-06463922	DMKM7EW	Minor	Increased metabolism of Ziprasidone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[51]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Osimertinib.	Lung cancer [2C25]	[49]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Selpercatinib.	Lung cancer [2C25]	[49]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Lumefantrine.	Malaria [1F40-1F45]	[49]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Halofantrine.	Malaria [1F40-1F45]	[75]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Chloroquine.	Malaria [1F40-1F45]	[49]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Hydroxychloroquine.	Malaria [1F40-1F45]	[49]
Quinine	DMSWYF5	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Quinine.	Malaria [1F40-1F45]	[49]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Primaquine.	Malaria [1F40-1F45]	[49]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[49]
Idelalisib	DM602WT	Minor	Decreased metabolism of Ziprasidone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[60]
IPI-145	DMWA24P	Minor	Decreased metabolism of Ziprasidone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[60]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[49]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Vemurafenib.	Melanoma [2C30]	[49]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and LGX818.	Melanoma [2C30]	[49]
Dabrafenib	DMX6OE3	Minor	Increased metabolism of Ziprasidone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[51]
Danazol	DML8KTN	Minor	Decreased metabolism of Ziprasidone caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[60]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Ziprasidone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[76]
Propranolol	DM79NTF	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Propranolol.	Migraine [8A80]	[57]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Ziprasidone and Lasmiditan.	Migraine [8A80]	[77]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Ziprasidone and Flibanserin.	Mood disorder [6A60-6E23]	[78]
Doxylamine	DMKOXFE	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Doxylamine.	Morning sickness disorder [SC00]	[50]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Panobinostat.	Multiple myeloma [2A83]	[49]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Ziprasidone and Thalidomide.	Multiple myeloma [2A83]	[79]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Siponimod.	Multiple sclerosis [8A40]	[54]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Fingolimod.	Multiple sclerosis [8A40]	[49]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Ozanimod.	Multiple sclerosis [8A40]	[49]
Rifabutin	DM1YBHK	Minor	Increased metabolism of Ziprasidone caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[51]
Bexarotene	DMOBIKY	Minor	Increased metabolism of Ziprasidone caused by Bexarotene mediated induction of CYP450 enzyme.	Mycosis fungoides [2B01]	[51]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Romidepsin.	Mycosis fungoides [2B01]	[49]
Fedratinib	DM4ZBK6	Minor	Decreased metabolism of Ziprasidone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[60]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Nilotinib.	Myeloproliferative neoplasm [2A20]	[49]
Imatinib	DM7RJXL	Minor	Decreased metabolism of Ziprasidone caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[60]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Dasatinib.	Myeloproliferative neoplasm [2A20]	[49]
Modafinil	DMYILBE	Minor	Increased metabolism of Ziprasidone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[80]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Phenindamine.	Nasopharyngitis [CA00]	[50]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Droperidol.	Nausea/vomiting [MD90]	[49]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Dimenhydrinate.	Nausea/vomiting [MD90]	[50]
Prochlorperazine	DM53SRA	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Prochlorperazine.	Nausea/vomiting [MD90]	[49]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Promethazine.	Nausea/vomiting [MD90]	[49]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Cyclizine.	Nausea/vomiting [MD90]	[50]
Palonosetron	DMBHMOX	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Palonosetron.	Nausea/vomiting [MD90]	[49]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Ziprasidone and Metoclopramide.	Nausea/vomiting [MD90]	[81]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Granisetron.	Nausea/vomiting [MD90]	[49]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Dolasetron.	Nausea/vomiting [MD90]	[49]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Ondansetron.	Nausea/vomiting [MD90]	[49]
Thiethylperazine	DMU3IET	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Thiethylperazine.	Nausea/vomiting [MD90]	[50]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Ziprasidone and Bupropion.	Nicotine use disorder [6C4A]	[82]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Entrectinib.	Non-small cell lung cancer [2C25]	[49]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Ziprasidone caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[83]
Chlorthalidone	DM4DMBT	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Chlorthalidone.	Oedema [MG29]	[62]
Metolazone	DMB39LO	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Metolazone.	Oedema [MG29]	[62]
Polythiazide	DMCH80F	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Polythiazide.	Oedema [MG29]	[62]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Levomethadyl Acetate.	Opioid use disorder [6C43]	[49]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Lofexidine.	Opioid use disorder [6C43]	[49]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Ziprasidone and Apraclonidine.	Optic nerve disorder [9C40]	[72]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Rucaparib.	Ovarian cancer [2C73]	[49]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Ziprasidone and Pentazocine.	Pain [MG30-MG3Z]	[66]
Dextropropoxyphene	DM23HCX	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Dextropropoxyphene.	Pain [MG30-MG3Z]	[49]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Ziprasidone and Oxymorphone.	Pain [MG30-MG3Z]	[66]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Ziprasidone and Levorphanol.	Pain [MG30-MG3Z]	[66]
Hydromorphone	DMHP21E	Major	Additive CNS depression effects by the combination of Ziprasidone and Hydromorphone.	Pain [MG30-MG3Z]	[66]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Ziprasidone and Dezocine.	Pain [MG30-MG3Z]	[66]
Codeine	DMJX6ZG	Major	Additive CNS depression effects by the combination of Ziprasidone and Codeine.	Pain [MG30-MG3Z]	[66]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Flavoxate.	Pain [MG30-MG3Z]	[50]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Ziprasidone and Nalbuphine.	Pain [MG30-MG3Z]	[66]
Buprenorphine	DMPRI8G	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Buprenorphine.	Pain [MG30-MG3Z]	[49]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Ziprasidone and Hydrocodone.	Pain [MG30-MG3Z]	[66]
Meperidine	DMX4GND	Major	Additive CNS depression effects by the combination of Ziprasidone and Meperidine.	Pain [MG30-MG3Z]	[66]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Ziprasidone and Oxycodone.	Pain [MG30-MG3Z]	[66]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Triclabendazole.	Parasitic worm infestation [1F90]	[49]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Ziprasidone when combined with Pergolide.	Parkinsonism [8A00]	[84]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Ziprasidone when combined with Opicapone.	Parkinsonism [8A00]	[84]
Tolcapone	DM8MNVO	Moderate	Additive CNS depression effects by the combination of Ziprasidone and Tolcapone.	Parkinsonism [8A00]	[84]
Ropinirole	DMA6S1D	Moderate	Additive CNS depression effects by the combination of Ziprasidone and Ropinirole.	Parkinsonism [8A00]	[84]
Biperiden	DME78OA	Moderate	Antagonize the effect of Ziprasidone when combined with Biperiden.	Parkinsonism [8A00]	[69]
Procyclidine	DMHFJDT	Moderate	Antagonize the effect of Ziprasidone when combined with Procyclidine.	Parkinsonism [8A00]	[69]
Entacapone	DMLBVKQ	Moderate	Antagonize the effect of Ziprasidone when combined with Entacapone.	Parkinsonism [8A00]	[84]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Ziprasidone when combined with Levodopa.	Parkinsonism [8A00]	[84]
Pramipexole	DMNMW9R	Moderate	Antagonize the effect of Ziprasidone when combined with Pramipexole.	Parkinsonism [8A00]	[84]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Pimavanserin.	Parkinsonism [8A00]	[49]
Bromocriptine	DMVE3TK	Moderate	Antagonize the effect of Ziprasidone when combined with Bromocriptine.	Parkinsonism [8A00]	[84]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Orphenadrine.	Parkinsonism [8A00]	[50]
Apomorphine	DMX38HQ	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Apomorphine.	Parkinsonism [8A00]	[49]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Ziprasidone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[85]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Ziprasidone and Lindane.	Pediculosis [1G00]	[86]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Methylscopolamine.	Peptic ulcer [DA61]	[50]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Ziprasidone and Famotidine.	Peptic ulcer [DA61]	[54]
Cabergoline	DMQ4HIN	Moderate	Antagonize the effect of Ziprasidone when combined with Cabergoline.	Pituitary gland disorder [5A60-5A61]	[84]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[87]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Lefamulin.	Pneumonia [CA40]	[49]
Hydrocortisone	DMGEMB7	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[62]
Lonafarnib	DMGM2Z6	Minor	Decreased metabolism of Ziprasidone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[60]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Degarelix.	Prostate cancer [2C82]	[49]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and ABIRATERONE.	Prostate cancer [2C82]	[49]
Nilutamide	DMFN07X	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Nilutamide.	Prostate cancer [2C82]	[49]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Enzalutamide.	Prostate cancer [2C82]	[49]
Flutamide	DMK0O7U	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Flutamide.	Prostate cancer [2C82]	[49]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Relugolix.	Prostate cancer [2C82]	[49]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Bicalutamide.	Prostate cancer [2C82]	[49]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Terazosin.	Prostate hyperplasia [GA90]	[57]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Tamsulosin.	Prostate hyperplasia [GA90]	[57]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Silodosin.	Prostate hyperplasia [GA90]	[57]
Alfuzosin	DMZVMKF	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Alfuzosin.	Prostate hyperplasia [GA90]	[49]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Levomepromazine.	Psychotic disorder [6A20-6A25]	[49]
Fluphenazine	DMIT8LX	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Fluphenazine.	Psychotic disorder [6A20-6A25]	[49]
Triflupromazine	DMKFQJP	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Triflupromazine.	Psychotic disorder [6A20-6A25]	[49]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Ziprasidone and Tolazoline.	Pulmonary hypertension [BB01]	[57]
Bosentan	DMIOGBU	Minor	Increased metabolism of Ziprasidone caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[51]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Ziprasidone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[88]
Sorafenib	DMS8IFC	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Sorafenib.	Renal cell carcinoma [2C90]	[49]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Ziprasidone when combined with Neupro.	Restless legs syndrome [7A80]	[84]
Cyproheptadine	DM92AH3	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Cyproheptadine.	Rheumatoid arthritis [FA20]	[50]
Dexamethasone	DMMWZET	Minor	Increased metabolism of Ziprasidone caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[51]
Nafcillin	DMN9RPO	Minor	Increased metabolism of Ziprasidone caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[51]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Ziprasidone and Fentanyl.	Sensation disturbance [MB40]	[66]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Vardenafil.	Sexual dysfunction [HA00-HA01]	[49]
Voxelotor	DMCS6M5	Minor	Decreased metabolism of Ziprasidone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[60]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Ziprasidone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[56]
Larotrectinib	DM26CQR	Minor	Decreased metabolism of Ziprasidone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[60]
Armodafinil	DMGB035	Minor	Increased metabolism of Ziprasidone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[80]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[49]
Epirubicin	DMPDW6T	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[49]
Cisplatin	DMRHGI9	Major	Increased risk of ventricular arrhythmias by the combination of Ziprasidone and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[62]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[49]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[49]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[49]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Pitolisant.	Somnolence [MG42]	[49]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[49]
Ibutilide	DMKXY2R	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[49]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Ziprasidone due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[89]
Anagrelide	DMSQ8MD	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Anagrelide.	Thrombocytosis [3B63]	[49]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Lenvatinib.	Thyroid cancer [2D10]	[49]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Papaverine.	Tonus and reflex abnormality [MB47]	[90]
Tizanidine	DMR2IQ4	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Tizanidine.	Tonus and reflex abnormality [MB47]	[49]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Ziprasidone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[88]
Elagolix	DMB2C0E	Minor	Increased metabolism of Ziprasidone caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[51]
Astemizole	DM2HN6Q	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[49]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[50]
Triprolidine	DM7SWIA	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Triprolidine.	Vasomotor/allergic rhinitis [CA08]	[50]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[50]
Clemastine	DMBZWQL	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Clemastine.	Vasomotor/allergic rhinitis [CA08]	[50]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[50]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[49]
Dexbrompheniramine	DMKVWGE	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Dexbrompheniramine.	Vasomotor/allergic rhinitis [CA08]	[50]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Ziprasidone and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[91]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[50]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Ziprasidone and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[50]
Disopyramide	DM5SYZP	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[49]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Procainamide.	Ventricular tachyarrhythmia [BC71]	[49]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Propafenone.	Ventricular tachyarrhythmia [BC71]	[49]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Flecainide.	Ventricular tachyarrhythmia [BC71]	[49]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Ziprasidone and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[49]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Phenoxyisopropanol	E00386	92839	Antimicrobial preservative
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Ammonium chloride	E00321	25517	Acidulant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Calcium silicate	E00533	21910000	Adsorbent; Anticaking agent; Diluent; Opacifying agent
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol distearate	E00395	110800	Emollient; Opacifying agent; Surfactant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ziprasidone 60 mg capsule	60 mg	Oral Capsule	Oral
Ziprasidone 20 mg capsule	20 mg	Oral Capsule	Oral
Ziprasidone 40 mg capsule	40 mg	Oral Capsule	Oral
Ziprasidone 80 mg capsule	80 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 59).
• [3] Emerging anxiolytics. Expert Opin Emerg Drugs. 2007 Nov;12(4):541-54.
• [4] Karim A: Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev. 1978;8(1):151-88. doi: 10.3109/03602537808993782.
• [5] BDDCS applied to over 900 drugs
• [6] FDA Approved Drug Products: Geodon (ziprasidone HCl)
• [7] Ziprasidone hydrocloride: what role in the management of schizophrenia? J Cent Nerv Syst Dis. 2011 Feb 15;3:1-16. doi: 10.4137/JCNSD.S4138. Print 2011.
• [8] Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH: The disposition and metabolism of [14C]fluconazole in humans. Drug Metab Dispos. 1991 Jul-Aug;19(4):764-7.
• [9] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [10] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [11] Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). JClin Psychopharmacol. 2008 Dec;28(6):608-17.
• [12] Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
• [13] Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8.
• [14] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [15] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [16] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [17] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [18] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [19] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [20] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [21] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [22] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [23] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [24] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [25] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [26] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [27] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [28] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [29] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [30] Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
• [31] Clinical pipeline report, company report or official report of Roche (2009).
• [32] 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
• [33] Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
• [34] The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
• [35] Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
• [36] A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
• [37] ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
• [38] AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.
• [39] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [40] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [41] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [42] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [43] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [44] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [45] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [46] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [47] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [48] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [49] Canadian Pharmacists Association.
• [50] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [51] Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A "The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers." Br J Clin Pharmacol 49(suppl 1) (2000): s65-70. [PMID: 10771457]
• [52] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [53] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [54] Cerner Multum, Inc. "Australian Product Information.".
• [55] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [56] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [57] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [58] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [59] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [60] Miceli JJ, Smith M, Robarge L, Morse T, Laurent A "The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers." Br J Clin Pharmacol 49(suppl 1) (2000): s71-6. [PMID: 10771458]
• [61] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
• [62] Product Information. Geodon (ziprasidone). Pfizer US Pharmaceuticals, New York, NY.
• [63] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [64] Multum Information Services, Inc. Expert Review Panel.
• [65] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [66] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [67] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [68] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [69] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
• [70] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [71] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [72] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [73] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [74] Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
• [75] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [76] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [77] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [78] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [79] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [80] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [81] Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
• [82] Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
• [83] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [84] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [85] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [86] Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
• [87] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [88] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [89] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [90] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [91] Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.